Neuromuscular dis­eases and pregnancy

Authors: E. Vlčková;  S. Voháňka;  A. Rajdová;  J. Bednařík
Authors place of work: Neurologická klinika LF MU a FN Brno
Published in the journal: Cesk Slov Neurol N 2019; 82(3): 252-264
Category: Minimonografie


Pregnancy may significantly change the course of several neuromuscular diseases and have an impact on their therapy (especially some immunosuppressive agents commonly used for the therapy of immune-mediated inflammatory diseases are contraindicated). On the contrary, many neuromuscular diseases may negatively influence pregnancy and increase the occurrence of some complications of pregnancy and delivery. Several neuromuscular diseases thus significantly increase the incidence of spontaneous abortion, preterm birth, abnormal fetal position/ presentation, increased postpartum hemorrhage, and the rate of cesarean sections or operative vaginal deliveries using pliers or vacuum extractor. Some of neuromuscular diseases may also have an important impact on a fetus, e. g. the diseases which potentially decrease the oxygen saturation of the mother’s arterial blood may lead to the intrauterine fetal hypoxia. Furthermore, some diseases may be transmitted to the newborn, either genetically or by the transplacental transmission of antibodies on fetus. This minimonography summarizes the current knowledge on mutual relationship of pregnancy and the most frequent groups of neuromuscular diseases – myasthenia gravis, inflammatory myopathies, muscular dystrophies, motor neuron diseases, Guillain-Barre syndrome and chronic inflamatory demyelinating neuropathy, hereditary neuropathies and the most frequent mononeuropathies related to pregnancy (carpal tunnel syndrome, Bell’s palsy and some other traumatic or compressive postpartum lesions of the peripheral nerves in pelvic region or in lower extremities). If available, the recommendations upon the follow-up and management of patients with neuromuscular diseases during and after pregnancy and delivery are also mentioned.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manu­script met the ICMJE “uniform requirements” for biomedical papers.


pregnancy – neuromuscular diseases – immunosuppressive agents – myasthenia gravis – myositis – muscular dystrophies – motor neuron disease – Guillain-Barre syndrome – hereditary sensory and motor neuropathy – carpal tunnel syndrome – mononeuropathies


1. Špalek P. Myasténia gravis a žena: tehotenstvo, pôrod, puerpérium a tranzitórna neonatálna myasténia. Neurol praxi 2014; 15(6): 296– 299.

2. Norwood F, Dhanjal M, Hill M et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty work­­ing group. J Neurol Neurosurg Psychiatry 2014; 85(5): 538– 543. doi: 10.1136/ jn­np-2013-305

3. Plauché WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 1991; 34(1): 82– 99.

4. Batocchi AP, Majolini L, Evoli A et al. Course and treatment of myasthenia gravis dur­­ing pregnancy. Neurology 1999; 52(3): 447– 452.

5. Djelmis J, Sostarko M, Mayer D et al. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002; 104(1): 21– 25.

6. Ducci RD, Lorenzoni PJ, Kay CS et al. Clinical fol­low-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord 2017; 27(4): 352– 357. doi: 10.1016/ j.nmd.2017.01.021.

7. ÚZIS ČR. Potraty 2014– 2015. Praha: ÚZIS ČR 2017.
[online]. Dostupné z URL: publikace/ potraty-2014– 2015.

8. Zeitlin J, Szamotulska K, Drewniak N et al. Preterm births time trends in Europe: study of 19 countries. BJOG 2013; 120(11): 1356– 1365. doi: 10.1111/ 1471-0528.12281.

9. Betrán AP, Ye J, Mol­ler AB et al. The increas­­ing trend in caesarean section rates: global, regional and national estimates: 1990– 2014. PLoS One 2016; 11(2): e0148343. doi: 10.1371/ journal.pone.0148343.

10. ÚZIS ČR. Rodička a novorozenec 2014– 2015. [online]. Praha: ÚZIS ČR 2017. Dostupné z URL: katalog/ zdravotnicka-statistika/ rodicka-novorozenec.

11. Jeon J, Na S. Vacuum extraction vaginal delivery: cur­rent trend and safety. Obstet Gynecol Sci 2017; 60(6): 499– 505. doi: 10.5468/ ogs.2017.60.6.499.

12. Hacohen Y, Jacobson LW, Byrne S et al. Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol Neuroim­munol Neuroinflamm 2014; 2(1): e57. doi: 10.1212/ NXI.0000000000000057.

13. Liu FC, Kuo CF, See LC et al. Familial aggregation of myasthenia gravis in af­fected families: a population-based study. Clin Epidemiol 2017; 9: 527– 535. doi: 10.2147/ CLEP.S146617.

14. Hoff JM, Daltveit AK, Gilhus NE. Artrogryposis multiplex congenita –  a rare fetal condition caused by maternal myasthenia gravis. Acta Neurol Scand 2006; 183 (Suppl): 26– 27. doi: 10.1111/ j.1600-0404.2006.00610.x.

15. Midelfart Hoff J, Midelfart A. Maternal myasthenia gravis: a cause for arthrogryposis multiplex congenita. J Child Orthop 2015; 9(6): 433– 435. doi: 10.1007/ s11832-015-0690-8.

16. Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescrib­­ing im­munosuppres­sion medication to pregnant women. Expert Opin Drug Saf 2014; 13(12): 1591– 1599. doi: 10.1517/ 14740338.2014.951326.

17. Levy RA, de Jesús GR, de Jesús NR et al. Critical review of the cur­rent recom­mendations for the treatment of systemic inflam­matory rheumatic dis­eases dur­­ing pregnancy and lactation. Autoim­mun Rev 2016; 15(10): 955– 963. doi: 10.1016/ j.autrev.2016.07.014.

18. Mateus S, Malheiro M, Santos MP et al. Dermatomyositis onset in the puerperium period. BMJ Case Rep 2015; 2015. pii: bcr2015211025. doi: 10.1136/ bcr-2015-211025.

19. Nagy-Vincze M, Vencovsky J, Lundberg IE et al. Preg­nancy outcome in idiopathic inflam­matory myopathy patients in a multicenter study. J Rheumatol 2014; 41(12): 2492– 2494. doi: 10.3899/ jrheum.140438.

20. Váncsa A, Ponyi A, Constantin T et al. Pregnancy outcome in idiopathic inflam­matory myopathy. Rheumatol Int 2007; 27(5): 435– 439. doi: 10.1007/ s00296-006-0239-8.

21. Mintz G. Dermatomyositis. Rheum Dis Clin North Am 1989; 15(2): 375– 382.

22. Gutr­rez G, Dagnino R, Mintz G. Polymyositis/ dermatomyositis and pregnancy. Arthritis Rheum 1984; 27(3): 291– 294.

23. Silva CA, Sultan SM, Isenberg DA. Pregnancy outcome in adult-onset idiopathic inflam­matory myopathy. Rheumatology (Oxford) 2003; 42(10): 1168– 1172. doi: 10.1093/ rheumatology/ keg318.

24. Kolstad KD, Fiorentino D, Li S et al. Pregnancy outcomes in adult patients with dermatomyositis and polymyositis. Semin Arthritis Rheum 2018; 47(6): 865– 869. doi: 10.1016/ j.semarthrit.2017.11.005.

25. Attarian S, Salort-Campana E, Nguyen K et al. Recom­mendations for the management of facioscapulohumeral muscular dystrophy in 2011. Rev Neurol (Paris) 2012; 168(12): 910– 918. doi: 10.1016/ j.neurol.2011.11.008.

26. Tawil R, van der Maarel S, Padberg GW et al. 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2010; 20(7): 471– 475. doi: 10.1016/ j.nmd.2010.04.007.

27. Argov Z, de Vis­ser M. What we do not know about pregnancy in hereditary neuromuscular disorders. Neuromuscul Disord 2009; 19(10): 675– 679. doi: 10.1016/ j.nmd.2009.07.004.

28. Srebnik N, Margalioth EJ, Rabinowitz R et al. Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy. Reprod Biomed Online 2014; 29(1): 94– 101. doi: 10.1016/ j.rbmo.2014.03.013.

29. Johnson NE, Hung M, Nas­ser E et al. The impact of pregnancy on myotonic dystrophy: a registry-based study. J Neuromuscul Dis 2015; 2(4): 447– 452. doi: 10.3233/ JND-150095.

30. Hoogerwaard EM, van der Wouw PA, Wilde AA et al. Cardiac involvement in car­riers of Duchen­ne and Becker muscular dystrophy. Neuromuscul Disord 1999; 9(5): 347– 351.

31. Dar­ras BT, Mil­ler DT, Urion DK. Dystrophinopathies. In: Adam MP, Ardinger HH, Pagon RA et al (eds). GeneReviews®. Seattle (WA): University of Washington 1993– 2017. [online]. Available from URL: https: / / books/ NBK1119.

32. Rudnik-Schöneborn S, Zer­res K. Outcome in pregnancies complicated by myotonic dystrophy: a study of 31 patients and review of the literature. Eur J Obstet Gynecol Reprod Biol 2004; 114(1): 44– 53. doi: 10.1016/ j.ejogrb.2003.11.025.

33. Geifman-Holtzman O, Bernstein IM, Capeless EL et al. Increase in fetal breech presentation in female car­riers of Duchen­ne muscular dystrophy. Am J Med Genet 1997; 73(3): 276– 278.

34. Awater C, Zer­res K, Rudnik-Schöneborn S. Pregnancy course and outcome in women with hereditary neuromuscular disorders: comparison of obstetric risks in 178 patients. Eur J Obstet Gynecol Reprod Biol 2012; 162(2): 153– 159. doi: 10.1016/ j.ejogrb.2012.02.020.

35. Elsheikh BH, Zhang X, Swoboda KJ et al. Pregnancy and delivery in women with spinal muscular atrophy. Int J Neurosci 2017; 127(11): 953– 957. doi: 10.1080/ 00207454.2017.1281273.

36. Rudnik-Schöneborn S, Zer­res K, Ignatius J et al. Pregnancy and spinal muscular atrophy. J Neurol 1992; 239(1): 26– 30.

37. Scalco RS, Vieira MC, da Cunha Filho EV et al. Amyotrophic lateral sclerosis and riluzole use dur­­ing pregnancy: a case report. Amyotroph Lateral Scler 2012; 13(5): 471– 472. doi: 10.3109/ 17482968.2012.673

38. Rooney JP, Vis­ser AE, D‘Ovidio F et al. A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR. Neurology 2017; 89(12): 1283– 1290. doi: 10.1212/ WNL.0000000000004390.

39. Auger N, Quach C, Healy-Profitós J et al. Early predictors of Guil­lain-Bar­ré syndrome in the life course of women. Int J Epidemiol 2018; 47(1): 280– 288. doi: 10.1093/ ije/ dyx181.

40. Sax TW, Rosenbaum RB. Neuromuscular disorders in pregnancy. Muscle Nerve 2006; 34(5): 559– 571. doi: 10.1002/ mus.20661.

41. Pacheco LD, Saad AF, Hankins GD et al. Guil­lain-Bar­ré syndrome in pregnancy. Obstet Gynecol 2016; 128(5): 1105– 1110. doi: 10.1097/ AOG.0000000000001716.

42. Chan LY, Tsui MH, Leung TN. Guil­lain-Bar­ré syndrome in pregnancy. Acta Obstet Gynecol Scand 2004; 83(4): 319–325.

43. Nelson LH, McLean WT Jr. Management of Landry-Guil­lain-Bar­ré syndrome in pregnancy. Obstet Gynecol 1985; 65 (Suppl 3): 25– 29.

44. Luijckx GJ, Vles J, de Baets M et al. Guil­lain-Bar­ré syndrome in mother and newborn child. Lancet 1997; 349(9044): 27.

45. Watson WJ, Katz VL, Bowes WA Jr. Plasmapheresis dur­­ing pregnancy. Obstet Gynecol 1990; 76 (3 Pt 1): 451– 457.

46. Clark AL. Clinical uses of intravenous im­munoglobulin in pregnancy. Clin Obstet Gynecol 1999; 42(2): 368– 380.

47. McCombe PA, McManis PG, Frith JA et al. Chronic inflam­matory demyelinat­­ing polyradiculoneuropathy as­sociated with pregnancy. Ann Neurol 1987; 21(1): 102– 104. doi: 10.1002/ ana.410210120.

48. Rudnik-Schöneborn S, Rohrig D, Nicholson G et al. Pregnancy and delivery in Charcot-Marie-Tooth dis­ease type 1. Neurology 1993; 43(10): 2011– 2016.

49. Hoff JM, Gilhus NE, Daltveit AK. Pregnancies and deliveries in patients with Charcot-Marie-Tooth dis­ease. Neurology 2005; 64(3): 459– 462. doi: 10.1212/ 01.WNL.0000150933.65709.96.

50. Padua L, Di Pasquale A, Pazzaglia C et al. Systematic review of pregnancy-related carpal tun­nel syndrome. Muscle Nerve 2010; 42(5): 697– 702. doi: 10.1002/ mus.21910.

51. Padua L, Coraci D, Er­ra C et al. Carpal tun­nel syndrome: clinical features, dia­gnosis, and management. Lancet Neurol 2016; 15(12): 1273– 1284. doi: 10.1016/ S1474-4422(16)30231-9.

52. Padua L, Aprile I, Caliandro P et al. Carpal tun­nel syndrome in pregnancy: multiperspective fol­low-up of
untreated cases. Neurology 2002; 59(10): 1643– 1646.

53. Mondel­li M, Ros­si S, Monti E et al. Prospective study of positive factors for improvement of carpal tun­nel syndrome in pregnant women. Muscle Nerve 2007; 36(6): 778– 783. doi: 10.1002/ mus.20863.

54. van Slobbe AM, Bohnen AM, Bernsen RM et al. Incidence rates and determinants in meralgia paresthetica in general practice. J Neurol 2004; 251(3): 294– 297. doi: 10.1007/ s00415-004-0310-x.

55. Hol­land J, Bernstein J. Bel­l‘s palsy. BMJ Clin Evid 2011; 2011. pii: 1204.

56. Monini S, Lazzarino AI, Iacolucci C et al. Epidemiology of Bel­l‘s palsy in an Italian health district: incidence and case-control study. Acta Otorhinolaryngol Ital 2010; 30(4): 198.

57. Phil­lips KM, Heiser A, Gaudin R et al. Onset of bel­l‘s palsy in late pregnancy and early puerperium is as­sociated with worse long-term outcomes. Laryngoscope 2017; 127(12): 2854– 2859. doi: 10.1002/ lary.26569.

58. Katz A, Sergienko R, Dior U et al. Bel­l‘s palsy dur­­ing pregnancy: is it as­sociated with adverse perinatal outcome? Laryngoscope 2011; 121(7): 1395– 1398. doi: 10.1002/ lary.21860.

59. Ragupathy K, Emovon E. Bel­l‘s palsy in pregnancy. Arch Gynecol Obstet 2013; 287(1): 177– 178. doi: 10.1007/ s00404-012-2506-0.

60. Salinas RA, Alvarez G, Daly F et al. Corticosteroids for Bel­l‘s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2010; 17(3): CD001942. doi: 10.1002/ 14651858.CD001942.pub4.

61. de Almeida JR, Al Khabori M, Guyatt GH
et al. Combined corticosteroid and antiviral treat­ment for Bell palsy: a systematic review and meta-analysis. JAMA 2009; 302(9): 985– 993. doi: 10.1001/ jama.2009.

62. Kofler M, Kronenberg MF. Bilateral femoral neuropathy dur­­ing pregnancy. Muscle Nerve 1998; 21(8): 1106– 1110.

63. Wong CA, Scavone BM, Dugan S et al. Incidence of postpartum lumbosacral spine and lower extremity nerve injuries. Obstet Gynecol 2003; 101(2): 279– 288.

64. Adelman JU, Goldberg GS, Puckett JD. Postpartum bilateral femoral neuropathy. Obstet Gynecol 1973; 42(6): 845– 850.

65. Babayev M, Bodack MP, Creatura C. Com­mon peroneal neuropathy secondary to squatt­­ing dur­­ing childbirth. Obstet Gynecol 1998; 91 (5 Pt 2): 830– 832

Dětská neurologie Neurochirurgie Neurologie
Článek Editorial

Článek vyšel v časopise

Česká a slovenská neurologie a neurochirurgie

Číslo 3

2019 Číslo 3

Nejčtenější v tomto čísle
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se